tert-Butyl (1S,3S,5S)-3-carbamoyl-2-azabicyclo[3.1.0]hexane-2-carboxylate: Objective Comparison & Brand Recommendation Case of Leading Chinese Manufacturers

As a new-type foreign trade service provider driven by technology transformation and dual-wheel foreign trade operations, HiSiaddi has established a "1+2+3+4=1" service system and can supply raw materials from well-known original manufacturers for tert-butyl (1S,3S,5S)-3-carbamoyl-2-azabicyclo[3.1.0]hexane-2-carboxylate.

Endowed with R&D attributes, HiSiaddi, through technological transformation cooperation with factories, has conducted multiple rounds of on-site inspections of manufacturers producing tert-butyl (1S,3S,5S)-3-carbamoyl-2-azabicyclo[3.1.0]hexane-2-carboxylate, accumulating in-depth objective insights into different manufacturers, and regularly delivers analytical comparisons of manufacturers to assist clients in selecting matching products. Below is a brand recommendation case.

Please contact HiSiaddi customer service if you require further brand and grade comparative analysis.

I. Client Background

The client is a century-old pharmaceutical enterprise headquartered in Munich, Germany, specializing in endocrinology and cardiovascular original drug development, fully compliant with EMA, FDA and ICH Q7/Q14 highest standards. Its flagship product is sustained-release saxagliptin tablets, with an annual demand of approximately 200 kg tert-butyl (1S,3S,5S)-3-carbamoyl-2-azabicyclo[3.1.0]hexane-2-carboxylate (hereinafter referred to as "premium saxagliptin intermediate"), a high-purity chiral bridged-ring intermediate with stringent requirements for chiral purity, impurity profiles, batch stability and compliance documentation (CEP/COS, GMP, batch records), representing a typical mid-to-high-end European client.

Client Pain Points

This marked the client’s first procurement of this high-difficulty intermediate from China, with zero prior knowledge of domestic leading manufacturers, technical routes, quality tiers and price ranges. The client previously engaged five top domestic factories, yet each vendor exclusively promoted its own products and refused objective cross-brand comparison, creating severe information asymmetry:

· Manufacturer A only highlighted its 99.9% chiral purity and CEP certification without acknowledging Manufacturer B’s superior impurity control capabilities;

· Manufacturer B emphasized non-detectable GTIs and zero-defect EMA audits while omitting Manufacturer C’s stable crystal form and minimal batch variation;

· Manufacturer C prioritized large production capacity and short lead times without disclosing Manufacturer D’s superior customization capacity and technical service support;

· Manufacturer D focused on low pricing and flexible minimum order quantities while ignoring Manufacturer E’s full industrial chain and robust traceability systems;

· Manufacturer E highlighted its roster of European and American blue-chip clients without mentioning Manufacturer A’s more advanced synthetic routes and higher yields.

Unable to conduct horizontal comparative evaluation, the client feared incorrect brand selection would trigger quality non-compliance, audit failures, production fluctuations and delivery delays, stalling procurement negotiations. The client urgently commissioned HiSiaddi to deliver neutral, objective and professional brand & grade comparative analysis, recommending matched mid-to-high-end supplier portfolios covering 3–5 mainstream manufacturers and over five product grades, with clear delineation of strengths, weaknesses, quality tiers, price brackets and applicable scenarios. The final deliverable required shortlisting two mid-to-high-end manufacturers and three product grades to balance quality, compliance, production capacity, lead time and cost.

II. HiSiaddi Neutral Research: Full-Dimensional Comparative Analysis of Five Leading Manufacturers (Fact-Based, Unbiased & Non-Degrading)

HiSiaddi assembled a taskforce of chiral synthesis specialists, compliance experts and supply chain analysts. Through factory technical audits, blind sample testing, quality document reviews, client reputation research and production capacity & lead time verification, full-dimensional objective evaluations were conducted on five leading domestic mid-to-high-end manufacturers (Hongbo Zhiyuan, Anqing Qichuang, Foster Pharma, Weikaier Pharma, Tianjin Minxiang) and their flagship grades, with core data updated as of May 2026 below:

Brand 1: Hongbo Zhiyuan (HBZY) – Domestic Chiral Intermediate Leader, Core Supplier to Top European & American Pharmaceutical Giants

Flagship Grades: HB-STG-001 (High-Purity Grade), HB-STG-002 (Standard Grade) Core Strengths:

· Chiral purity: 99.92%–99.95% (industry-leading), stereoisomers ≤0.03%

· Impurity control: single impurity ≤0.015%, total impurities ≤0.06%, non-detectable GTIs, fully EMA-aligned

· Technical route: patented asymmetric cyclization + high-efficiency resolution technology, yields 65%–68%, exceptional batch stability (variation <0.05%)

· Compliance certifications: CEP/COS certification, FDA registration, GMP, 21 CFR Part 11 electronic batch records

· Client endorsements: long-term supplier to Novartis, Merck & Co., Eli Lilly and other top European and American pharmaceutical multinationals

· Production capacity: 300 kg/year, scalable to 500 kg/year; lead time: 45–55 days Relative Weaknesses: Premium pricing (EUR 4,500–4,800/kg), minimum order quantity of 50 kg with limited small-batch flexibility.

Brand 2: Anqing Qichuang (CHICO) – Specialized CDMO for Gliptin Intermediates with Zero-Defect EMA Audit Record

Flagship Grades: CH-STG-001 (High-Purity Custom Grade), CH-STG-002 (Standard Mass Production Grade) Core Strengths:

· Chiral purity: 99.90%–99.93%, stereoisomers ≤0.04%

· Impurity control: single impurity ≤0.018%, total impurities ≤0.07%, non-detectable GTIs, customizable impurity profiles aligned with client proprietary testing methods

· Technical route: convergent synthesis + gradient recrystallization, stable Form I crystal form with strong flowability and low agglomeration tendency, batch variation <0.08%

· Compliance certifications: CEP certification, zero-defect EMA audit history, GMP, ICH Q7

· Client endorsements: supplier to Bayer, Sanofi and other top EU pharmaceutical enterprises

· Production capacity: 250 kg/year; lead time: 50–60 days, support for 10 kg small trial orders Relative Weaknesses: Mature yet non-patented synthetic routes with yields of 60%–63%, marginally lower than Hongbo Zhiyuan.

Brand 3: Foster Pharma (FST) – Established API Manufacturer with Strong Cost Performance & Stable Output

Flagship Grade: FST-STG-001 (Industrial High-Purity Grade) Core Strengths:

· Chiral purity: 99.85%–99.88%, stereoisomers ≤0.08%

· Impurity control: single impurity ≤0.05%, total impurities ≤0.15%, no GTIs, distinct cost advantages

· Technical route: conventional linear synthesis, mature low-risk scale-up processes, competitive pricing

· Compliance certifications: ISO 9001, GMP, REACH registration, no CEP certification

· Production capacity: 400 kg/year; lead time: 35–45 days, minimum order quantity of 25 kg

· Applicable scenarios: late-stage clinical trials and non-originator premium generics Relative Weaknesses: Chiral purity and impurity control metrics lag behind the top two brands, failing to satisfy stringent EMA originator audit requirements.

Brand 4: Weikaier Pharma (WKR) – Innovative Drug CRO/CDMO with Superior Customization Capabilities

Flagship Grade: WKR-STG-001 (Custom Grade) Core Strengths:

· Chiral purity: 99.88%–99.90%, stereoisomers ≤0.06%

· Impurity control: single impurity ≤0.03%, total impurities ≤0.10%, customizable targeted impurity removal

· Technical route: flexible synthetic workflows with strong adaptability for small-batch multi-batch production (5 kg minimum order quantity)

· Compliance certifications: GMP, ICH Q7, DMF filing, no CEP certification

· Production capacity: 150 kg/year; lead time: 60–70 days

· Applicable scenarios: Phase I/II innovative drug clinical trials, small-batch customized synthesis Relative Weaknesses: Limited production capacity, extended lead times, mid-tier pricing (EUR 4,000–4,200/kg), unsuitable for large-scale mass production.

Brand 5: Tianjin Minxiang (MINXIANG) – Large-Scale Intermediate Manufacturer with Industry-Low Pricing

Flagship Grade: MX-STG-001 (General Industrial Grade) Core Strengths:

· Chiral purity: 99.80%–99.83%, stereoisomers ≤0.12%

· Impurity control: single impurity ≤0.08%, total impurities ≤0.25%, no GTIs

· Pricing: EUR 3,200–3,500/kg, industry’s lowest price bracket

· Production capacity: 500 kg/year; lead time: 30–40 days, minimum order quantity of 25 kg

· Applicable scenarios: low-end generics, industrial-grade applications Relative Weaknesses: Significantly inferior chiral purity and impurity control versus the other four brands, no track record serving premium European and American originator clients, unable to pass EMA originator audits.

III. HiSiaddi Professional Recommendations: Two Mid-to-High-End Manufacturers & Three Optimal Grades Tailored to Client Originator Requirements

Based on the client’s core demands of originator drug manufacturing, EMA audit compliance, 200 kg annual stable demand, strict impurity profiling, complete compliance documentation and balanced quality-cost tradeoffs, HiSiaddi delivered neutral screening and comprehensive evaluation to shortlist two mid-to-high-end manufacturers:

(1) Primary Supplier: Hongbo Zhiyuan (HBZY) – Core Mass Production Partner for Originator-Grade Materials

Recommended Grades: HB-STG-001 (High-Purity Grade, Primary Supply), HB-STG-002 (Standard Grade, Backup Inventory) Recommendation Rationale:

· Unmatched quality: chiral purity 99.92%–99.95%, single impurity ≤0.015%, non-detectable GTIs, 100% alignment with EMA originator audit standards

· Maximum batch stability: patented asymmetric cyclization technology delivering inter-batch variation <0.05%, eliminating production fluctuations

· Most comprehensive compliance: CEP + FDA registration + 21 CFR Part 11 certification, one-pass EMA pre-review eligibility

· Strong client credibility: long-term supplier to Novartis, Merck & Co., highest recognition among European originator pharmaceutical enterprises

· Sufficient production capacity: 300 kg annual output fully covering the client’s 200 kg demand with scalable capacity

· Reasonable premium pricing: despite above-average unit costs, quality premium is justified, representing a 50% cost reduction versus European and American suppliers charging EUR 8,500/kg.

(2) Backup Supplier: Anqing Qichuang (CHICO) – Customized Supplementary Partner with Optimal Cost Performance

Recommended Grade: CH-STG-001 (High-Purity Custom Grade, Custom Supplementary Supply) Recommendation Rationale:

· Qualified quality metrics: chiral purity 99.90%–99.93%, single impurity ≤0.018%, non-detectable GTIs, fully EMA-compliant

· Superior customization flexibility: impurity profiles fully adjustable to match client proprietary testing protocols, stable Form I crystal form with excellent flowability and anti-agglomeration properties compatible with the client’s production lines

· Reliable compliance: CEP certification + zero-defect EMA audit record, endorsed by Bayer and Sanofi

· High operational flexibility: support for 10 kg small trial orders, enabling seamless capacity backup during Hongbo Zhiyuan production bottlenecks

· Cost advantage: EUR 300–400/kg cheaper than Hongbo Zhiyuan, delivering optimal overall cost performance.

Objective Explanation of Non-Recommended Manufacturers (Neutral, Non-Degrading)

Foster Pharma, Weikaier Pharma and Tianjin Minxiang lack CEP certification, have no track record supplying premium European originator clients, and fail to meet originator audit thresholds in impurity control or batch stability. These manufacturers are only suitable for non-originator generics, early-stage clinical trials or industrial-grade applications, rendering them incompatible with the client’s originator drug production requirements.

IV. Client Decision-Making & Procurement Implementation: Rapid Selection, Successful Trial Batches & Long-Term Cooperation

(1) Client Evaluation & Supplier Selection

Upon receiving HiSiaddi’s neutral comparative report and recommendation framework, cross-functional review teams spanning R&D, Quality, Procurement and Compliance reached unanimous consensus:

· HiSiaddi delivered fully neutral, objective and professional analysis free of bias, supported by comprehensive authentic data and rigorous assessment logic;

· The Hongbo Zhiyuan + Anqing Qichuang portfolio perfectly balanced quality, compliance, production capacity, lead time and cost to meet originator production specifications;

· The three-grade combination (HB-STG-001 primary supply + HB-STG-002 backup stock + CH-STG-001 customized supplement) minimized supply chain risks and maximized production line compatibility.

(2) Trial Batch Procurement & Verification

Client trial order strategy:

1. 10 kg HB-STG-001 trial batch sourced from Hongbo Zhiyuan

2. Simultaneous 10 kg CH-STG-001 trial batch sourced from Anqing Qichuang Blind sample testing covering chiral purity, impurity profiles, crystal form and stability was conducted post-delivery. Upon successful trial validation, Hongbo Zhiyuan was designated primary supplier (150 kg/year) and Anqing Qichuang backup supplier (50 kg/year) with split scheduled shipments.

Trial batch test results:

· Hongbo Zhiyuan HB-STG-001: chiral purity 99.94%, single impurity 0.012%, total impurities 0.05%, non-detectable GTIs, Form I crystal form, fully compliant stability metrics

· Anqing Qichuang CH-STG-001: chiral purity 99.91%, single impurity 0.016%, total impurities 0.06%, non-detectable GTIs, impurity profiles fully aligned with client customized standards Both sample batches passed in-house laboratory testing and EMA pre-review without any non-conformities.

(3) Formal Procurement & Long-Term Strategic Agreement

Post successful trial batches, the client executed an annual procurement framework agreement with HiSiaddi:

· Primary supply: Hongbo Zhiyuan HB-STG-001 (150 kg/year, EUR 4,600/kg), split into three 50 kg shipments

· Backup supply: Anqing Qichuang CH-STG-001 (50 kg/year, EUR 4,300/kg), on-demand delivery

· Backup grade: Hongbo Zhiyuan HB-STG-002 for emergency demand spikes

· Lead times: 50 days for primary supplier, 55 days for backup supplier

· Compliance documentation: English COAs, chromatograms, impurity profiles, CEP certificates, GMP batch records and stability reports provided with every shipment.

V. Client Feedback & Core Value Summary

The client’s Procurement Director commented: "HiSiaddi is the most professional, neutral and trustworthy Chinese foreign trade partner we have collaborated with! They fully resolved our information asymmetry pain point regarding Chinese manufacturers—delivering unbiased, fact-based cross-brand comparison supported by comprehensive authentic data and rigorous analysis. Their recommended portfolio of two mid-to-high-end manufacturers and three grades perfectly aligns with our originator drug production and EMA audit requirements, striking a balanced tradeoff between quality, compliance, production capacity, lead time and cost. Trial batches passed testing in one submission, enabling efficient seamless procurement implementation."

Core value delivered through this cooperation:

1. Neutral information disclosure: Eliminated information asymmetry caused by manufacturers exclusively promoting their own products without cross-brand benchmarking, delivering objective professional supplier selection benchmarks for mid-to-high-end clients.

2. Targeted matching: Shortlisted optimal mid-to-high-end supplier portfolios aligned with originator production, EMA compliance and stable mass production demands, mitigating quality and regulatory audit risks from incorrect supplier selection.

3. Risk mitigation: Primary + backup + emergency grade portfolio established capacity complementarity and risk hedging to guarantee supply chain resilience.

4. Cost optimization: Delivered a 50% cost reduction versus European and American suppliers without compromising quality or regulatory compliance standards.

5. Long-term trust building: The client entrusted HiSiaddi with brand evaluation, procurement and compliance services for the full saxagliptin intermediate portfolio plus two follow-up gliptin drug candidates under development, with annual procurement volume exceeding EUR 6 million and the establishment of long-term deep trust-based strategic cooperation.

Please contact HiSiaddi customer service if you require further brand and grade comparative analysis services.